塩酸フラボキサート製剤(ブラダロン錠)の泌尿器科領域の使用経験 - とくに著効例と無効例についての検討 -

Abstract

Flavoxate hydrochloride (Bladderon) was administered to 150 patients (inpatients and outpatients) who had come to our department complaining of voiding disorder. The overall clinical efficacy was assessed to be excellent in 41 patients (27.3%), good in 42 patients (28.0%), fair in 10 patients (6.7%) and poor in 57 patients (38.0%); excellent and good response being seen in 83 patients (55.3%). Bladderon was more effective for cystitis, benign prostatic hypertrophy, nervous pollakisuria and nephroptosis: and the symptomatic improvement was remarkable for urinary frequency especially nocturia. This proves the clinical usefulness of Bladderon. The adequate dosage of Bladderon was 3-6 tablets daily although in cases of urinary bladder carcinoma, a daily dose of 9-12 tablets failed to lower urinary frequency. There tended to be more excellently responding cases among the younger patients, while there tended to be more poorly responding cases among the aged patients. Drug-related side effects were observed in 9 patients, but all of them were mild gastrointestinal disorders. A comparative study of the cases with excellent and poor responses revealed the prospectiveness of the clinical application of this drug. In follow-up study in the cases judged as poor must be made in future to evaluate the proper indications of this drug.